Evidence map›Paper›PMID 34663357›Full record

ArticleParticle and fibre toxicology2021

Sex affects the response of Wistar rats to polyvinyl pyrrolidone (PVP)-coated silver nanoparticles in an oral 28 days repeated dose toxicity study.

Marija Ćurlin, Rinea Barbir, Sanja Dabelić, Marija Ljubojević, Walter Goessler, Vedran Micek, Irena Žuntar, Mirela Pavić, Lucija Božičević, Ivan Pavičić and 1 more

Abstract read
In one paragraph

Article in Particle and fibre toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Amphiphilic Poly-Pharmaceutics · 2022
    Article
  8. Sex and Gender Dimensions in Hazard and Risk Assessment of Engineered Nanomaterials.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marija ĆurlinSchool of Medicine, University of Zagreb, Šalata 3, 10 000, Zagreb, Croatia. marija.curlin@mef.hr.ORCID 0000-0002-3418-3058
Rinea BarbirInstitute for Medical Research and Occupational Health, Ksaverska cesta 2, 10 000, Zagreb, Croatia.
Sanja DabelićFaculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, 10 000, Zagreb, Croatia.
Marija LjubojevićInstitute for Medical Research and Occupational Health, Ksaverska cesta 2, 10 000, Zagreb, Croatia.
Walter GoesslerInstitute of Chemistry, University of Graz, Universitätsplatz 1/1, 8 010, Graz, Austria.
Vedran MicekInstitute for Medical Research and Occupational Health, Ksaverska cesta 2, 10 000, Zagreb, Croatia.
Irena ŽuntarFaculty of Pharmacy and Biochemistry, University of Zagreb, Ante Kovačića 1, 10 000, Zagreb, Croatia.
Mirela PavićFaculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10 000, Zagreb, Croatia.
Lucija BožičevićInstitute for Medical Research and Occupational Health, Ksaverska cesta 2, 10 000, Zagreb, Croatia.
Ivan PavičićInstitute for Medical Research and Occupational Health, Ksaverska cesta 2, 10 000, Zagreb, Croatia.
Ivana Vinković VrčekInstitute for Medical Research and Occupational Health, Ksaverska cesta 2, 10 000, Zagreb, Croatia. ivinkovic@imi.hr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSilver nanoparticles (AgNPs) are widely used in biomedicine due to their strong antimicrobial, antifungal, and antiviral activities. Concerns about their possible negative impacts on human and environmental health directed many researchers towards the assessment of the safety and toxicity of AgNPs in both in vitro and in vivo settings. A growing body of scientific information confirms that the biodistribution of AgNPs and their toxic effects vary depending on the particle size, coating, and dose as well as on the route of administration and duration of exposure. This study aimed to clarify the sex-related differences in the outcomes of oral 28 days repeated dose exposure to AgNPs.

methodsWistar rats of both sexes were gavaged daily using low doses (0.1 and 1 mg Ag/kg b.w.) of polyvinylpyrrolidone (PVP)-coated small-sized (10 nm) AgNPs. After exposure, blood and organs of all rats were analysed through biodistribution and accumulation of Ag, whereas the state of the liver and kidneys was evaluated by the levels of reactive oxygen species (ROS) and glutathione (GSH), catalase (CAT) activity, superoxide dismutase (SOD) and glutathione peroxidase (GPx), expression of metallothionein (Mt) genes and levels of Mt proteins.

resultsIn all animals, changes in oxidative stress markers and blood parameters were observed indicating the toxicity of AgNPs applied orally even at low doses. Sex-related differences were noticed in all assessed parameters. While female rats eliminated AgNPs from the liver and kidneys more efficiently than males when treated with low doses, the opposite was observed for animals treated with higher doses of AgNPs. Female Wistar rats exposed to 1 mg PVP-coated AgNPs/kg b.w. accumulated two to three times more silver in the blood, liver, kidney and hearth than males, while the accumulation in most organs of digestive tract was more than ten times higher compared to males. Oxidative stress responses in the organs of males, except the liver of males treated with high doses, were less intense than in the organs of females. However, both Mt genes and Mt protein expression were significantly reduced after treatment in the liver and kidneys of males, while they remained unchanged in females.

conclusionsObserved toxicity effects of AgNPs in Wistar rats revealed sex-related differences in response to an oral 28 days repeated exposure.

Indexed as

Metal NanoparticlesPovidoneAnimalsFemaleMalePolyvinylsRatsRats, WistarSilverTissue DistributionPolyvinylsPovidoneSilverAccumulationMetallothioneinOxidative stressToxicityWistar rat

Identifiers

PMID34663357
PMCPMC8522010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.